FDA Approves New Ophthalmic Treatment for Wet Macular Degeneration

The U.S. Food and Drug Administration has granted approval for LYTENAVA™, an ophthalmic formulation of bevacizumab, to treat wet Age-related Macular Degeneration (AMD). This marks the first and only FDA-approved eye-specific bevacizumab, offering retina specialists and patients a new treatment option backed by rigorous clinical evidence.